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Inactivation of androgen-induced regulator ARD1
inhibits androgen receptor acetylation and
prostate tumorigenesis
Zehua Wanga,b,1, Zemin Wanga,1, Jianhui Guoa,1, Yingchun Lia, Jasmin H. Bavarvaa, Chiping Qiana,
M. Christiane Brahimi-Hornc, Deyong Tanb,2, and Wanguo Liua,2
a
Department of Genetics and Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112; bLaboratory of
Biochemistry and Molecular Biology, School of Life Science, Yunnan University, Kunming 650091, China; and cInstitute of Developmental Biology and Cancer
Research, Centre A Lacassagne, Centre National de la Recherche Scientiﬁque, Unité Mixte de Recherche 6543, University of Nice, 06189 Nice, France

Androgen signaling through androgen receptor (AR) is critical for
prostate tumorigenesis. Given that AR-mediated gene regulation is
enhanced by AR coregulators, inactivation of those coregulators
is emerging as a promising therapy for prostate cancer (PCa). Here,
we show that the N-acetyltransferase arrest-defect 1 protein (ARD1)
functions as a unique AR regulator in PCa cells. ARD1 is up-regulated
in human PCa cell lines and primary tumor biopsies. The expression
of ARD1 was augmented by treatment with synthetic androgen
(R1881) unless AR is deﬁcient or is inhibited by AR-speciﬁc siRNA
or androgen inhibitor bicalutamide (Casodex). Depletion of ARD1
by shRNA suppressed PCa cell proliferation, anchorage-independent growth, and xenograft tumor formation in SCID mice, suggesting that AR-dependent ARD1 expression is biologically germane.
Notably, ARD1 was critical for transcriptionally regulating a number
of AR target genes that are involved in prostate tumorigenesis.
Furthermore, ARD1 interacted physically with and acetylated the
AR protein in vivo and in vitro. Because AR–ARD1 interaction facilitated the AR binding to its targeted promoters for gene transcription, we propose that ARD1 functions as a unique AR regulator and
forms a positive feedback loop for AR-dependent prostate tumorigenesis. Disruption of AR–ARD1 interactions may be a potent intervention for androgen-dependent PCa therapy.
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A

ndrogen signaling, particularly the androgen receptor (AR)
activity plays a crucial role in prostate cancer (PCa) development. The primary role of AR in PCa is believed to regulate expression of the genes that are essential for prostate
tumorigenesis. As a transcriptional factor, after binding to androgen, AR binds to speciﬁc DNA sequences and consequently
recruits RNA polymerase II and a basal transcriptional complex
for efﬁcient transcription of AR target genes. Deregulation of
the AR target genes such as PSA, SLC45A3, FASN, and
TMPRSS2 has been shown to promote PCa cell growth and tumorigenesis (reviewed in ref. 1).
AR-mediated transcriptional regulation is dependent on AR
activity, which is often deregulated through mechanisms such as
mutations in the AR gene, increased expression of AR protein,
growth factor-induced activation of AR, or aberrant function of
AR-interacting proteins, particularly the coactivators. AR coactivators enhance AR activity and PCa cell survival through
phosphorylation, sumoylation, and stabilization of AR (reviewed
in ref. 2). Recently, AR acetylation was found to play a key role in
AR-mediated transactivation and prostate tumorigenesis (3).
Acetylases that are AR coactivators include p300, a histone acetylase, the p300–CBP-associated factor (P/CAF), and the Tat
interactive protein 60 (TIP60). They acetylate AR at three individual residues, lysine 630, 632, and 633 in a conserved lysine
motif of AR (630KLKK633) (3–5). Following AR acetylation, these
proteins facilitate AR transcriptional activity by remodeling
chromatin via histone acetylation and by recruiting RNA polymerase II complex to the AR-regulated promoters (3, 6). Like
other AR coactivators, acetylases such as p300 are up-regulated in
www.pnas.org/cgi/doi/10.1073/pnas.1113356109

PCa (7). Up-regulation of p300 enhances AR acetylation, which is
critical for AR activity to regulate AR target genes leading to PCa
progression (3). Thus, aberrant activation of AR in PCa has been
attributed, at least in part, to up-regulation of AR coactivators
such as acetylases. Emerging evidence indicates that inhibition of
AR coactivators is an effective antiandrogen therapy (8). Recently, it has become evident that inactivation of p300 inhibits
prostate tumorigenesis (9). Therefore, identifying new AR coactivators and elucidating their roles in androgen signaling through
AR may provide a critical drug target for therapeutic intervention in PCa.
In a genetic analysis of DNA damage response genes in PCa,
we previously found that ARD1 was not mutated but rather upregulated in PCa (10). ARD1 induces acetylation in a large group
of proteins that contain the N-α– or ε-acetylation sites (11). By
acetylating speciﬁc substrate proteins, ARD1 plays important
roles in apoptosis, hypoxia, autophagy, and cell proliferation (12–
15). Signiﬁcantly, recent reports indicate that dysregulation of
ARD1 is associated with tumorigenesis in a variety of human
cancers including colorectal (16), breast (14), and lung (15, 17).
However, the role of ARD1 in PCa remains unknown.
In this study, we identiﬁed ARD1 as a unique androgen-induced
AR regulator in PCa. By overexpressing or silencing ARD1, we
demonstrated that ARD1 is crucial for AR-mediated gene transcription, PCa cell proliferation, and xenograft tumor growth.
Importantly, we revealed an important role of ARD1 in prostate
tumorigenesis through its interaction with and acetylation of AR.
Our ﬁndings suggest that dysregulation of ARD1 may contribute
to AR-mediated gene transcription and PCa development and
that ARD1 is a potential therapeutic target for PCa.
Results
ARD1 Is Up-Regulated in PCa Cell Lines and Tumor Tissues. To de-

termine the role of ARD1 in prostate tumorigenesis, we ﬁrst
measured ARD1 protein levels in 12 prostatic epithelial cell lines
by Western blotting. Levels of ARD1 were higher in all 9 PCa
cell lines than in 3 normal prostatic epithelial cell lines (Fig. 1A,
Left). Moreover, ARD1 levels were the highest in cell lines with
intact AR (LNCaP, C4-2B, and MDA-PCa 2b) (Fig. 1A, Left).
The average level of ARD1 was more than doubled in PCa cell
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Fig. 1. ARD1 is up-regulated in PCa cell
lines and tumor tissues. (A) AR and ARD1
levels in prostate cell lines were determined
by Western blotting (Left) and by dosimetric
analysis of the Western bands (Right). β-Actin was used as the loading control in all
Western blot analyses in this study. (B) ARD1
protein levels were determined in 12 paired
prostate tumors and matched normal prostate tissues by Western blotting (Left) and by
quantiﬁcation of the Western bands (Right).
(C) Representative microphotograph of IHC
analysis of ARD1 in prostate tissue microarray. Images a–d represent IHC staining in
normal prostate and grade I–III PCa tissues.
The histogram shows the percentage of
positive IHC staining of ARD1 in 17 normal
and 64 PCa tissues. (Magniﬁcation: C, ×200.)
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lines with intact AR compared with those without and was approximately ﬁvefold higher than that in the normal prostate cell
lines (Fig. 1A, Right). The high levels of ARD1 were also observed
by Western blotting in 11 of 12 freshly frozen prostate tumor
tissues compared with their matched adjacent normal prostate
tissues (Fig. 1B, Left). The levels of ARD1 in the majority of PCa

tissues were more than doubled those in the matched normal
tissues (Fig. 1B, Right). For clinical relevance, we performed immunohistochemistry (IHC) on a PCa tissue microarray and
revealed high levels of ARD1 in 62/64 (∼97%) of tumor tissues but
only in 1/17 (∼6%) of normal prostate tissues had a positive
staining (Fig. 1C and Table S1). Taken together, these data

Fig. 2. Androgen activates ARD1 in an AR-dependent manner. (A) LNCaP, DU-145, and PC-3 cells were androgen starved
in 10% charcoal-dextran stripped FBS (CDS–FBS) for 2 d and
then treated with R1881 at indicated doses for 24 h before
Western blotting with anti-ARD1 and anti-AR antibodies. (B)
Androgen-starved DU-145 and PC-3 cells were treated with
ethanol as vehicle or 1 nM R1881 following transfection with
pcDNA3.1-AR or pcDNA3.1 vector, respectively, for 24 h before
Western blotting. (C) Androgen-starved LNCaP cells were
treated with a series of doses of R1881 at the times indicated
before Western blotting. PSA was used as a positive control.
(D) Androgen-starved LNCaP cells were treated for 24 h with
either R1881 or R1881 plus androgen receptor antagonist
(CDX) as indicated. The expression levels of ARD1 and AR were
analyzed by Western blotting. (E) Androgen-starved LNCaP
cells were transfected with either control or AR-speciﬁc siRNA
for 48 h and then treated with vehicle or 1 nM R1881 for
another 24 h before Western blot analysis.

3054 | www.pnas.org/cgi/doi/10.1073/pnas.1113356109
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Fig. 3. Silencing ARD1 inhibits prostate tumorigenesis. (A) LNCaP cells were
stably transfected with lentiviral shARD1 or a scramble shRNA. The ARD1
knockdown efﬁciency was assessed by Western blotting using anti-ARD1
antibody. (B) Growth curves of the stable LNCaP cell lines. Cell numbers were
determined at the indicated days using Trypan blue counting. Values represent mean ± SD of three independent experiments performed in triplicates.
*P < 0.01 according to Student’s t test for all three cell lines. (C) Representative microphotographs of colonogenic assays of stable LNCaP cells as in A. A
total of 5 × 103 cells were cultured at 37 °C for 2 wk and colonies were stained
with Crystal violet. (D) Anchorage-independent growth assay of stable LNCaP
cells as in A. A total of 500 cells per well mixed in medium with agarose and
seeded into 12-well plates were cultured for 14 d as described previously (24).
Representative photographs are shown. (E) Representative photograph
showing the xenograft tumor in NOD/SCID mice injected with control-shRNAexpressing (Left ﬂank) or shARD1-expressing (Right ﬂank) stable LNCaP cells
(Left) and tumor volume measured weekly (Right). (Scale bar, 5 mm.)
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indicate that ARD1 is up-regulated in PCa, and ARD1 may serve
as a useful protein marker for prostate tumorigenesis.
Androgen Activates ARD1 in an AR-Dependent Manner in PCa. As the
PCa cell lines with intact AR showed the highest levels of ARD1, we
hypothesized that ARD1 might be induced by androgen. We ﬁrst
excluded that ARD1 was induced by androgen at the transcriptional level (Fig. S1 A and B). We then treated PCa cell lines with
synthetic androgen (R1881) and found that ARD1 was induced at
the protein level in LNCaP cells but not in AR-null PC-3 and DU145 cells (Fig. 2A). However, R1881 induced ARD1 in both DU145 and PC-3 cells when AR was ectopically expressed (Fig. 2B).
The dose–response and time-course experiments in LNCaP cells
revealed that ARD1 was induced about 8 h after R1881 stimulation
and gradually up-regulated as the level of AR increased (Fig. 2C).
The dose- and time-dependent induction of ARD1 by dihydrotestosterone (DHT) was also observed (Fig. S1C). Using androgen inhibitor Casodex (CDX) or AR silencing by AR-speciﬁc
siRNA in LNCaP cells, we further demonstrated that ARD1 induction by androgen was signiﬁcantly decreased without AR (Fig. 2
D and E). These results demonstrate that up-regulation of ARD1
in PCa is induced by androgen in an AR-dependent manner.
ARD1 Induces PCa Cell Proliferation, Oncogenicity, and Xenograft
Tumor Growth. Next, we investigated the role of ARD1 up-reg-

ulation in prostate tumorigenesis. We compared the cell growth
Wang et al.

ARD1 Regulates AR-Mediated Transcription. PCa cell growth is believed to be regulated by AR-mediated transcription. We therefore examined the role of ARD1 in transcriptional regulation of
AR target genes using prostate-speciﬁc antigen (PSA) and mouse
mammary tumor virus (MMTV) luciferase reporter assays. As
expected, the luciferase activities of both reporters were signiﬁcantly induced in LNCaP cells stimulated with R1881 and in PC-3
cells following ectopic expression of AR (Fig. S3 A and B). Conversely, the activities of the two reporters were signiﬁcantly reduced in LNCaP cells following ARD1 silencing but increased in
an ARD1 dose-dependent fashion in PC-3 cells following coexpression of AR and ARD1 (Fig. S3 C and D). Consistent with the
reporter assay results, quantitative real-time (qRT-PCR) analysis
of 12 known AR target genes revealed that following R1881
treatment and ARD1 silencing in LNCaP cells, the mRNA levels
of the 4 AR down-regulated genes (FN1, ACPP, UGT2B13, and
UGT2B17) were activated (Fig. 4A). In contrast, the 8 AR upregulated genes including PSA, TMPRSS2, SLC45A3, FASN,
ABHD2, ALDH1A3, FKBP5, and NDRG1 were down-regulated,
respectively, in comparison with the mRNA levels in the control
cells without silencing of ARD1 (Fig. 4A). The mRNA level of the
TMPRSS2 gene was reduced by almost 80%, whereas the transcriptional activation of the UGT2B17 gene was increased more
than 10-fold (Fig. 4A). To determine whether ARD1 acts as an AR
coactivator, we performed PSA luciferase reporter assays in
LNCaP cells that express AR and in PC-3 cells that lack endogenous AR expression. As expected, overexpression of ARD1 in
LNCaP cells resulted in ∼3-fold activation of the PSA reporter,
whereas silencing AR by AR-speciﬁc siRNA abolished the effect
of ARD1 on the reporter activity (Fig. S3E). In PC-3 cells, expression of ARD1 alone had no signiﬁcant effect on the reporter
(Fig. S3F). Remarkably, coexpression of ARD1 and AR resulted
in >5-fold activation of the reporter compared with the cells
expressing ARD1 alone (Fig. S3F). These results suggest that
ARD1-mediated transactivation of PSA requires AR. This conclusion was further validated by qRT-PCR analysis of the transcription levels of 2 AR target genes, PSA and TMPRSS2.
Consistent with the reporter data, expression of ARD1 increased
PSA or TMPRSS2 transcription by >3- or >4-fold, respectively, but
the inductions were completely abolished when AR was silenced
by siRNA (Fig. 4B). Furthermore, we performed ChIP analysis
and showed that overexpression of ARD1 in LNCaP cells facilitated AR to interact with the PSA or TMPRSS2 promoter, compared with that in the cells without overexpression of ARD1 (Fig.
4C). Together, these results demonstrated that ARD1-induced
PNAS | February 21, 2012 | vol. 109 | no. 8 | 3055
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rates between three LNCaP clones stably expressing ARD1speciﬁc shRNA and three stable clones expressing a control
scramble shRNA. We found that the cell growth rates for the
stable transfectants with ARD1 shRNA were signiﬁcantly reduced compared with the stable transfectants with control
shRNA (Fig. 3 A and B). Consistently, the stable transfectants
with the ARD1 shRNA formed almost none or a signiﬁcantly
lower number of colonies than the control stable transfectants
(Fig. 3C). Similar results were obtained when pooled stable
clones were used (Fig. S2). To assess the oncogenicity of ARD1,
we performed anchorage-independent colony formation assays
on soft agar. Intriguingly, the stable transfectants with the ARD1
shRNA did not generate any foci, whereas the controls generated signiﬁcantly more and larger foci (Fig. 3D). Furthermore,
we implanted male SCID mice with stable transfectants
expressing the ARD1 shRNA or control shRNA on the right or
left hind ﬂank of each mouse, respectively. Consistent with the
in vitro data, silencing ARD1 in LNCaP cells completely suppressed xenograft tumor growth, whereas the tumor volumes
increased daily for the control LNCaP cells (Fig. 3E). Together,
these data strongly suggest that ARD1 is an oncoprotein in PCa
and that silencing of ARD1 reduces PCa cell proliferation
and oncogenicity.

Fig. 4. Inactivation of ARD1 inhibits AR target gene expression. (A) LNCaP cells transfected with shARD1 were androgen
starved for 2 d and treated with vehicle or 1 nM R1881 for 16 h
before RNA isolation and qRT-PCR analysis. The mRNA levels in
cells expressing control shRNA without treatment of R1881
were plotted as 1. The levels less than a 14-fold difference (Left)
and those over a 14-fold difference (Right) were plotted. Values
represent mean ± SD of three independent experiments performed in triplicate in all experiments. (B) LNCaP cells transfected with ARD1 expression construct or control vector (LacZ)
following AR silencing with AR-speciﬁc siRNA for 48 h and
treated with 1 nM R1881 for an additional 24 h. PSA and
TMPRSS2 mRNA levels were measured by qRT-PCR (P < 0.01 for
both). (C) Androgen-starved LNCaP cells were transfected with
ARD1 or a control vector for 2 d and treated with 1 nM R1881 for
24 h. Cells were ﬁxed and chromatin sheared and precleared.
ChIP assay was then performed with indicated antibodies. Values represent mean ± SD of three independent experiments.
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PCa cell growth is probably through transcriptional activation
of the AR target genes, suggesting that ARD1 functions as an
AR regulator.
ARD1 Acetylates AR for Target Gene Transcription. To understand
the mechanism by which ARD1 promotes AR-mediated gene
transcription, we examined AR level or stability following downregulation of ARD1. Intriguingly, silencing ARD1 did attenuate
the PSA level but seemed to have no effect on AR level (Fig.
S4A). Because ARD1 is an acetyltransferase, we hypothesized
that ARD1 might exert its regulatory activity by acetylating AR.
Reciprocal coimmunoprecipitation analyses of endogenous or
exogenous proteins of ARD1 and AR in 293T and LNCaP cells
demonstrated that ARD1 physically interacted with AR in vivo
and in vitro (Fig. 5 A and B). Using acetylation-speciﬁc antibody,
we discovered that silencing ARD1 in LNCaP cells inhibited AR
acetylation signiﬁcantly (Fig. 5C). To determine whether ARD1mediated AR acetylation is ARD1 speciﬁc, we generated the
catalytically inactive (acetyltransferase null) ARD1 mutant
(ARD1 dead) as previously described (14). Expression of the
ARD1-dead mutant remarkably reduced the level of acetylated
AR (Fig. 5D). To conﬁrm the role of ARD1 in AR acetylation,
we performed an in vitro acetylation assay using puriﬁed
recombinant full-length AR as the substrate, the immunoprecipitated WT-ARD1, or ARD1 dead as the enzyme, and acetylCoA as the coenzyme. We showed that ARD1 directly acetylates
AR in vitro but not ARD1 dead (Fig. 5E). Finally, we examined
the possible link between AR acetylation by ARD1 and AR
target gene transcription. We demonstrated that the ARD1-dead
mutant was unable to induce either PSA promoter activity or PSA
transactivation in LNCaP cells by luciferase reporter assay (Fig.
5F) or by qRT-PCR (Fig. 5G), respectively. Moreover, ARD1dead mutant reduced the ability of AR to bind to the PSA promoters shown by ChIP analysis (Fig. 5H). These results indicate
that AR acetylation by ARD1 is required for ARD1-induced AR
target gene transcription and prostate tumorigenesis.
3056 | www.pnas.org/cgi/doi/10.1073/pnas.1113356109

Discussion
In this study, we reveal a unique role for ARD1 as an AR regulator
in prostate tumorigenesis. We show that AR–ARD1 interaction
and ARD1-dependent AR acetylation are required for transcriptional activation of AR target genes in vivo and in vitro. Silencing ARD1 in LNCaP cells results in marked inhibition of AR
target gene transcription, PCa cell proliferation, and xenograft
tumor growth. The signiﬁcance of AR acetylation by ARD1 is
further substantiated by demonstrating that silencing ARD1 or
expressing an ARD1-dead mutant reduces AR acetylation and
leads to reduction of AR-targeted promoter interaction and ARtarget gene expression (Fig. 5). It has been reported that AR can
be acetylated by p300 at AR lysine residues 630, 632, and 633
(KLKK) for ligand-dependent AR activation (3). Intriguingly, silencing p300 did reduce the level of total AR but did not attenuate
the level of ARD1-acetylated AR (Fig. S4B). Moreover, mutant
AR in which the three lysine residues (KLKK633) were replaced by
glutamine still can be acetylated by ARD1 (Fig. S4C). These data
suggest that the AR acetylation site(s) for ARD1 might be different from that for p300. Further analysis will be required to
identify the ARD1-speciﬁc acetylation site in AR to better understand the mechanisms by which ARD1 acetylates AR to promote AR-mediated transcription and prostate tumorigenesis.
Similar to many other AR coregulators, ARD1 is overexpressed in PCa. Although we observed the highest levels of
ARD1 in PCa cell lines with AR, the levels of ARD1 in ARnegative cell lines were also relatively higher than those in the
normal prostatic epithelial cell lines. It has been reported that
two distinct sets of genes are activated in AR-dependent versus
AR-independent PCa cells (18). It will be interesting to determine whether the other set of genes in AR-independent PCa
cells is regulated by ARD1 through a non-AR–dependent signaling pathway. Furthermore, we observed that ARD1 was upregulated in 97% (62/64) of PCa biopsies but in only 6% (1/17)
of benign prostate tissues, highlighting the clinical signiﬁcance of
Wang et al.
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Fig. 5. Acetylation of AR by ARD1 is required for AR-mediated gene transcription. (A) Protein interaction of ARD1 with AR proteins in vitro. Flag–ARD1 and
His–AR were cotransfected in 293T cells, and reciprocal immunoprecipitation and immunoblotting were carried out with the indicated antibodies. (B) Interaction of endogenous ARD1 and AR proteins in LNCaP cells. Reciprocal coimmunoprecipitation and immunoblotting were performed with antibodies as
indicated. (C) Silencing ARD1 by shRNA inhibits AR acetylation. LNCaP cells were transduced with lentiviral shARD1 and treated with 10 mM sodium butyrate
to prevent protein deacetylation. Cell lysates were immunoprecipitated; total and acetylated AR was measured by Western blotting. (D) Acetyltransferasenull ARD1 mutant inhibits AR acetylation. AR cotransfected with WT ARD1 or ARD1-dead mutant in 293T cells was immunoprecipitated, and the acetylated
AR was detected with anti-acetyl lysine antibody. (E) Commercially purchased AR and Acetyl-CoA were incubated in the acetylation buffer with WT ARD1 or
ARD1 dead, which was harvested and puriﬁed by immunoprecipitation from LNCaP cells transfected with WT-ARD1 or ARD1-dead expression construct,
respectively (details described in Materials and Methods). The reaction mixtures were subjected to SDS-PAGE and blotted using indicated antibodies. (F)
Luciferase activity assay of the PSA promoter (P < 0.01). (G) qRT-PCR analysis of PSA mRNA level (P < 0.05), and (H) ChIP analysis of AR and PSA promoter
interaction were conducted in LNCaP cells expressing ARD1-dead mutant in comparison with the cells expressing WT ARD1.

ARD1 expression in PCa. However, in our analysis of this cohort, we did not observe a correlation between the level of
ARD1 and the grade of PCa. This was somehow expected that
the number of grade IV tumors with strong expression of ARD1
would be reduced compared with tumors with grade II or III
because some of the grade IV tumors might lose AR during the
PCa progression. Future analyses of large sample sets of PCa
biopsies are warranted to evaluate the potential application of
ARD1 as a protein marker for PCa initiation and progression.
The data reported in this study support ARD1 as an oncoprotein in PCa, rather than as a tumor suppressor, which was
recently described in breast cancer (14). The tumor-suppressive
role of ARD1 in breast cancer was shown by clinical signiﬁcance
of ARD1 mRNA expression, loss of heterozygosity (LOH) at the
ARD1 locus, and by functional signiﬁcance of ARD1 in suppression of the mammalian target of rapamycin signaling pathway (14). In contrast, we did not detect LOH at the ARD1 locus
in 12 pairs of PCa tumor specimens, nor did we detect decreased
pS6K1 (T389) phosphorylation by ARD1 in LNCaP cells (Fig.
S5). The tumor-promoting role of ARD1 was also recently described in lung cancer via acetylation and activation of β-catenin
to promote cyclin D1 expression (15). Because ARD1 is an
acetyltransferase and exerts its function through its target proteins, it is very likely that the role of ARD1 in cancer is tissue
speciﬁc or cell-type dependent and relies on its acetylating
substrates.
Wang et al.

In summary, our ﬁndings suggest that ARD1 is a quite unique
AR regulator. It achieves its oncogenic role in prostate tumorigenesis through a positive feedback mechanism. Following ARdependent activation by androgen, ARD1 activates AR through
AR–ARD1 interaction and AR acetylation. By linking the
overexpression of ARD1 in PCa and ARD1-dependent acetylation of AR to AR-mediated transcription, our study provides
a unique avenue for controlling AR-mediated prostate tumorigenesis by direct inhibition of ARD1 expression or AR–ARD1
interaction. Therefore, developing ARD1-speciﬁc inhibitor or
AR–ARD1 interaction-disrupting peptide may be of therapeutic
beneﬁt in the treatment of PCa.
Materials and Methods
Cell Lines and Tissue Specimens. HEK293T, LNCaP, DU145, PC-3, 22Rv1, MDA
PCa 2b, NCI-H660, and RWPE-2 cell lines were purchased from American Type
Culture Collection (ATCC); P69, M12, M2182, and C4-2B cell lines were
generously provided by Shahriar Koochekpour (Louisiana State University
Health Sciences Center, New Orleans, LA); BPH-1 cell line was from Haojie
Huang (Masonic Cancer Center, Minneapolis, MN). The cell lines were
maintained in appropriate media according to the ATCC’s protocols. The
human PCa tissues were collected in the Louisiana Cancer Research Consortium with institutional review board approval. The prostate tissue
microarray was purchased from US Biomax.
IHC, Immunoblotting, and Immunoprecipitation. IHC analyses of the human
tissue microarray was conducted as previously described (19) using the ARD1
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antibody (20). Immunoblotting and immunoprecipitation were performed
as described (21). The antibodies used in this study are provided in SI
Materials and Methods.
Plasmids and Transient or Stable Transfection of Cells. The Flag–ARD1expressing construct was generated by inserting hARD1 cDNA into pCMV–
Tag2b vector (Stratagene) with BamHI/HindIII restriction sites. The acetyltransferase-null ARD1 mutant (ARD1 dead) was established by substituting
Ala for both Arg82 and Gly85 as previously described (22). Luciferase reporter plasmids for PSA (PSA–Luc), MMTV (MMTV–Luc), and pcDNA3.1–His
-hAR were provided by Haojie Huang. Transient transfection of plasmids
or siRNAs was performed using X-tremeGENE HP DNA transfection reagent
(Roche) according to the manufacturer’s instructions. Lentiviral constructs
expressing ARD1-speciﬁc shRNA or a control scramble shRNA were generated
by inserting the reported sequences (23) into the pLKO.1 vector (Addgene)
with the AgeI/EcoRI restriction sites. The lentiviral particle preparation and
the LNCaP cell lines stably expressing control or ARD1 shRNA were established on the basis of the protocol previously described (19).
Cell Proliferation and Anchorage-Independent Growth Assays. Cells were
plated at a density of 2 × 105 cells per well in 6-cm dishes. Cells were trypsinized at days 2, 4, and 6 and counted using a hemocytometer stained with
trypan blue. Clonogenic growth of cells was evaluated by assessing plating
efﬁciency for anchorage-independent growth in soft agar at day 16 after
plating, as described previously (24).
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Xenograft Tumor Growth. Stable LNCaP cells expressing shARD1 or shControl
were collected in 100 μL sterile PBS and ECM gel (Sigma) mixture (50/50, vol/
vol) and inoculated subcutaneously into the right (shARD1) and left (control)
ﬂank of 5-wk-old nonobese diabetic (NOD)/SCID mice (Charles River) at 3.0 ×
106 cells per injection site (n = 5 for each group). Mice were monitored twice
a week for tumor development. Tumor size was measured weekly using a
caliper. Eight weeks after inoculation, mice were killed in keeping with the
policy of the humane treatment of tumor-bearing animals. All procedures
follow an animal use protocol approved by the Institutional Animal Care
and Use Committee of Louisiana State University Health Sciences Center
New Orleans.

Quantitative RT-PCR. Total RNAs were prepared with RNeasy mini kit (Qiagen)
and cDNA was synthesized with SuperScript III First-Strand synthesis system
(Invitrogen). Quantitative RT-PCR (qRT-PCR) was performed with SYBR Green
detection method on a CFX96 Real-Time PCR Detection system (Bio-Rad). All
of the primers used for qRT-PCR in this study are provided (Table S2).
Chromatin Immunoprecipitation. ChIP assay was performed as previously
described (21) with modiﬁcations. Brieﬂy, LNCaP cells were grown in phenol
red-free RPMI-1640 medium with 10% FBS (charcoal stripped) for 3 d and
treated with 1 nM R1881 or vehicle for 24 h. Prepared chromatin was
immunoprecipitated with anti-AR or anti-IgG antibody at 4 °C overnight.
The precipitated DNA was PCR ampliﬁed with primers corresponding to
PSA enhancer or corresponding to the androgen-responsive elements of
TMPRSS2, as previously described (25, 26). The relative enrichment was
shown using agarose gel electrophoresis.
In Vitro Acetylation Assay. The in vitro acetylation assay on AR was performed
using ARD1, as described previously with modiﬁcation (2, 4). Brieﬂy, LNCaP cells
grown in 100-mm culture dishes were transfected with 10 μg of pCMV-tag2bWT-ARD1 or pCMV-tag2b-ARD1-dead expression plasmid, respectively, using
X-tremeGENE HP reagent and cultured for 2 d. Cells were harvested and puriﬁed for WT ARD1 and ARD1 dead by immunoprecipitation with anti-Flag
antibody (Sigma). The in vitro acetylation assay was performed in acetylation
buffer [50 mM Tris-HCl (pH 8.0), 1 mM phenylmethylsulfonyl ﬂuoride, 10%
glycerol, 10 mM butyric acid, 0.2 mM EDTA, 1 mM DTT] containing 250 ng
of substrate (HIS–AR; Abcam) and enzyme (the immunoprecipitated ARD1)
and 1 μL acetyl-CoA (Sigma). The mixture was incubated at 30 °C for 1 h. The
reaction mixtures were subjected to SDS-polyacrylamide gel electrophoresis
and blotted using antiacetyl-lysine primary and corresponding secondary
antibodies.
Statistical Analysis. Data are expressed as mean ± SD from at least three
experiments. Statistical analyses were performed by Student t test. P < 0.05
was considered statistically signiﬁcant.

Luciferase Reporter Assay. Cells transfected with a combination of plasmids or
siRNA, PSA–Luc, or MMTV–Luc reporter and an internal control (pRL–TK) as
described in the ﬁgure legend section were harvested for luciferase activity
analyses using the Dual-Luciferase Reporter Assay system (Promega) following the manufacturer’s instructions.
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